• ELISpot Development Modules
• ELISpot Kits

Introduction

R&D Systems' ELISpot kits are highly sensitive, microplate-based assays for the detection of cytokine secreting cells. Complete ELISpot kits are ready-to-run and require no assay development or refinement. ELISpot Development Modules contain matched antibodies for the development of a working assay. Additional supplies are required and assay development expertise is recommended.

Features

• Detect and quantitate individual cells secreting specific analytes
• High sensitivity-can measure responses with frequencies well below 1/100,000 cells
• No in vitro expansion of cells required
• High-throughput-ELISpot assays use only a small volume of primary cells

Complete Kit Components

• Coated PVDF-backed 96-well Microplate
• Detection Antibody
• Streptavidin-AP
• BCIP/NBT
• Positive Control
• Dilution Buffers
• Wash Buffer

ELISpot Development Modules

ELISpot development modules are an alternative to ELISpot kits. A basic understanding of ELISpot assay development is required for the successful use of these reagents. Each investigator should optimize the experimental conditions, such as cell type, cell stimulation conditions and cell dilutions for each assay. The type of enzyme and substrate, as well as the concentrations of the capture and detection antibodies can give varied results.

The analyte-specific ELISpot Development Modules and the ELISpot Blue Color Module contain the necessary components for analyte detection and visualization, respectively. These modules can be used together but are sold separately. Each module contains enough reagents for at least 5 96-well microplates.

• Capture Antibody Concentrate
• Detection Antibody Concentrate

• Streptavidin-AP
• BCIP/NBT

References

1. Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle. Abdul-Wahid, A. et al. (2007) Vaccine 25:8372.
   Sample Type: mouse lymphocytes
   Catalog #: SEL404, SEL485

2. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Chong, S.Y. et al. (2007) Vaccine 25:4967.
   Sample Type: rhesus macaque peripheral blood leukocytes
   Catalog #: SEL202

3. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. Andreson, M.J. et al. (2007) J. Immunol. 178:1268.
   Sample Type: mouse T cells
   Catalog #: SEL1865

4. Cell-mediated immune responses to COPV early proteins.  Jain, S. et al. (2006) Virology 356:23.
   Sample Type: canine lymphocytes
   Catalog #: SEL781

5. Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. Powell, N.D. et al. (2005) J. Immunol. 175:5611.
   Sample Type: mouse splenocytes
   Catalog #: SEL417

6. Nitric oxide mediates T cell cytokine production and signal transduction in histidine decarboxylase knockout mice. Koncz, A. et al. (2007) J. Immunol. 179:6613.
   Sample Type: mouse splenocytes
   Catalog #: EL404, EL485, EL417

7. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Yu, D.H. et al. (2007) Vaccine 25:6744.
   Sample Type: mouse EL4 lymphoma cell line
   Catalog #: EL1865

8. Inhibition of matrix metalloproteinases protects mice from ascending infection and chronic disease manifestations resulting from urogenital Chlamydia muridarum infection. Imtiaz, M.T. et al. (2006) Infect. Immun. 74:5513.
   Sample Type: mouse single-cell suspension of uterus and oviduct cells
   Catalog #: EL909

9. Generation of tumor-reactive effector lymphocytes using tumor RNA-introduced dendritic cells in gastric cancer patients. Ohshita, A. et al. (2006) Int. J. Oncol. 28:1163.
   Sample Type: human dendritic cells
   Catalog #: EL285

10. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. Correale, J. et al. (2005) J. Neuroimmunol. 162:173.
    Sample Type: human peripheral blood mononuclear cells
    Catalog #: EL217, EL206, EL285